The effectiveness of Response-guided therapy strategies in recent hepatitis C infection.
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms ATAHC-II
- 01 Sep 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 25 May 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12611000513910), additional centre and investigator added, additional identifier added.
- 18 Apr 2011 New trial record